Please assess the completion status of the following clinical trial:

Trial Title: PRecision Interventions for SMoking in the SCCS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Daily smoker of ≥5 cigarettes per day (CPD)~* Enrolled participant of the Southern Community Cohort Study (SCCS) who completed a prior survey indicating they were willing to be contacted regarding a smoking cessation clinical trial~* Residence in Tennessee (TN) or Mississippi (MS)~* Has stored blood sample with the SCCS~* Has established primary care provider (PCP)~* Medically eligible and willing to take varenicline and NRT~Exclusion Criteria:~* Currently taking medication to quit smoking~* enrolled, or planning to be enrolled, in another smoking cessation program~* Inability to give informed consent or participate due to cognitive disorder (e.g., dementia, severe intellectual disability)~* Unstable psychiatric illness (ER or hospitalized for psychiatric condition in past 6 months, change in psychiatric medications in past 3 months, or suicidal ideation in past 6 months)~* not able to send or receive mail~* no access to a telephone or inability to communicate by telephone~* unable to speak and read English~* history of seizures or Buerger's disease~* currently pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Guideline-Based Care (GBC) (Type: OTHER): GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
- Nicotine Metabolite Ratio (PC-NMR) (Type: ACTIVE_COMPARATOR): Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
- Respiragene (PC-Respiragene) (Type: ACTIVE_COMPARATOR): Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).